SAFETY AND EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN G CONTAINING HIGH ANTI-WEST

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objective: To assess and characterized the safety and tolerability of Omr-IgG-am TM in a population of hospitalized patients with confirmed or suspected WNV disease Secondary Objective: To assess pharmacokinectics of specific anti-West Nile antibodies following intravenous administration of Omr-IgG-am TM To estimate efficacy of Omr-IgG-am TM in reducing morbidity and mortality, for patients with known or suspected WNV infection who receive WNV specific IVIg versus similar patients who receive either placebo To further characterize the natural history of sever WNV infection